Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib and Methotrexate PK Study
NCT03402087Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 14 days, Time to attain maximum observed plasma concentration at 14 days and 5 more. Started Jan 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03402087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402087.